14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $2.85 $4.97 Tuesday, 23rd Apr 2024 ALDX stock ended at $3.91. This is 0.509% less than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 7.20% from a day low at $3.89 to a day high of $4.17.
90 days $2.71 $4.97
52 weeks $1.42 $11.97

Historical Aldeyra Therapeutics prices

Date Open High Low Close Volume
Apr 23, 2024 $3.94 $4.17 $3.89 $3.91 451 658
Apr 22, 2024 $3.91 $4.04 $3.81 $3.93 368 661
Apr 19, 2024 $3.96 $3.99 $3.79 $3.86 422 886
Apr 18, 2024 $3.97 $4.07 $3.89 $3.98 427 349
Apr 17, 2024 $3.91 $4.15 $3.83 $3.97 632 747
Apr 16, 2024 $4.02 $4.10 $3.84 $3.87 724 552
Apr 15, 2024 $4.26 $4.33 $4.05 $4.16 494 861
Apr 12, 2024 $4.36 $4.47 $4.19 $4.25 576 926
Apr 11, 2024 $4.30 $4.48 $4.22 $4.40 570 384
Apr 10, 2024 $4.30 $4.30 $4.10 $4.25 637 629
Apr 09, 2024 $4.55 $4.68 $4.33 $4.43 1 049 304
Apr 08, 2024 $4.95 $4.95 $4.30 $4.38 1 025 161
Apr 05, 2024 $4.68 $4.97 $4.58 $4.72 1 463 806
Apr 04, 2024 $4.54 $4.88 $4.35 $4.69 2 518 761
Apr 03, 2024 $3.65 $4.22 $3.61 $4.15 2 282 133
Apr 02, 2024 $3.28 $3.56 $3.20 $3.55 1 059 177
Apr 01, 2024 $3.30 $3.37 $3.13 $3.27 318 783
Mar 28, 2024 $3.12 $3.50 $3.12 $3.27 850 627
Mar 27, 2024 $2.95 $3.14 $2.89 $3.08 303 027
Mar 26, 2024 $2.94 $2.96 $2.89 $2.92 257 044
Mar 25, 2024 $2.93 $2.98 $2.85 $2.88 278 061
Mar 22, 2024 $2.95 $2.95 $2.87 $2.90 201 393
Mar 21, 2024 $2.98 $3.03 $2.90 $2.91 300 189
Mar 20, 2024 $2.84 $2.94 $2.77 $2.92 251 069
Mar 19, 2024 $2.78 $2.89 $2.75 $2.85 364 179
Click to get the best stock tips daily for free!

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria... ALDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT